{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "E",
          "alt": "K",
          "position": "46"
        },
        "variant_string_id": "SNCA E46K"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Lewy bodies composed of aggregates of α-synuclein (αS) in the brain are the main histopathological features of Lewy body diseases (LBD) such as Parkinson's disease and dementia with Lewy bodies.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay being described for the E46K variant, linking αS aggregation to LBD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "To answer this question, we examined the aggregation including monomer conformational dynamics and oligomerization of the E46K, A30P, A53T and A30P/A53T mutations and wild type (WT) using thioflavin S assay, circular dichroism spectroscopy, photo-induced cross-linking of unmodified proteins, electron microscopy, and atomic force microscopy.",
          "judgment": "Yes",
          "reasoning": "The general class of assay used (aggregation and oligomerization studies) effectively models the disease pathogenesis/mechanism defined in Step 1.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Relative to WT αS, E46K αS accelerated the kinetics of the secondary structure change and oligomerization, whereas A30P αS decelerated them. These effects were reflected in changes in average oligomer size. The mutant oligomers of E46K αS functioned as fibril seeds significantly more efficiently than those of WT αS, whereas the mutant oligomers of A30P αS were less efficient.",
          "judgment": "Yes",
          "reasoning": "The paper provides detailed results from the assays, showing significant differences in behavior between the E46K variant and WT, indicating the assay's validity.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The mutant oligomers of E46K αS functioned as fibril seeds significantly more efficiently than those of WT αS.",
          "judgment": "Yes",
          "reasoning": "The E46K variant shows a clear pathogenic effect by accelerating fibril formation and increasing oligomer size, which is consistent with the disease mechanism.",
          "next_step_or_outcome": "Assign PS3 strength"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The E46K variant in SNCA accelerates the kinetics of secondary structure change and oligomerization, and its oligomers function as more efficient fibril seeds than WT, supporting a pathogenic role with moderate strength (PS3_moderate)."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Lewy bodies composed of aggregates of α-synuclein (αS) in the brain are the main histopathological features of Lewy body diseases (LBD) such as Parkinson's disease and dementia with Lewy bodies.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay being described for the A30P variant, linking αS aggregation to LBD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "To answer this question, we examined the aggregation including monomer conformational dynamics and oligomerization of the E46K, A30P, A53T and A30P/A53T mutations and wild type (WT) using thioflavin S assay, circular dichroism spectroscopy, photo-induced cross-linking of unmodified proteins, electron microscopy, and atomic force microscopy.",
          "judgment": "Yes",
          "reasoning": "The general class of assay used (aggregation and oligomerization studies) effectively models the disease pathogenesis/mechanism defined in Step 1.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Relative to WT αS, E46K αS accelerated the kinetics of the secondary structure change and oligomerization, whereas A30P αS decelerated them. These effects were reflected in changes in average oligomer size. The mutant oligomers of E46K αS functioned as fibril seeds significantly more efficiently than those of WT αS, whereas the mutant oligomers of A30P αS were less efficient.",
          "judgment": "Yes",
          "reasoning": "The paper provides detailed results from the assays, showing significant differences in behavior between the A30P variant and WT, indicating the assay's validity.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The mutant oligomers of A30P αS were less efficient as fibril seeds than those of WT αS.",
          "judgment": "Yes",
          "reasoning": "The A30P variant shows a decelerating effect on fibril formation and decreases oligomer size, which is consistent with a pathogenic role by altering the aggregation process.",
          "next_step_or_outcome": "Assign PS3 strength"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A30P variant in SNCA decelerates the kinetics of secondary structure change and oligomerization, and its oligomers function as less efficient fibril seeds than WT, supporting a pathogenic role with supporting strength (PS3_supporting)."
    }
  ]
}